» Articles » PMID: 38410029

Erectile Dysfunction Prevalence in the United States: Report from the 2021 National Survey of Sexual Wellbeing

Overview
Journal J Sex Med
Date 2024 Feb 27
PMID 38410029
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There has been a great deal of public speculation regarding a surge in erectile dysfunction (ED) in younger men despite data consistently indicating that the ED prevalence rates increase with age.

Aim: In this study we sought to assess the prevalence and risk of experiencing ED in a nationally representative sample of men in the United States across various social groups, describe comorbidities, and examine barriers to treatment.

Methods: Data from the 2021 National Survey of Sexual Wellbeing were analyzed by utilizing the Ipsos KnowledgePanel®, a probability-based online panel, for the purpose of obtaining US nationally representative data of adults aged 18 years and older. The analytic sample consisted of 1822 cisgender men ranging in age from 18 to 87 years, with a mean age of 47.5 years.

Outcomes: Study outcomes were ED as measured by the 5-item version of the International Index of Erectile Function (IIEF-5), as well as self-reported diagnosis by a medical professional, comorbidities with other health issues, medications taken for ED, and barriers to treatment.

Results: The ED prevalence rate based on IIEF-5 scores was 24.2%. Prevalence increased with age: 52.2% of the 75+ age group, and 48.0% of the 65-74 age group meeting diagnostic criteria for ED. Diagnostic criteria were met for more participants in the 18-24 age group (17.9%) than the 25-34 (13.3%) or 35-44 (12.7%) age groups, but less than the 45-54 (25.3%) or 55-64 (33.9%) age groups. Only 7.7% (n = 141) of the sample reported having been diagnosed by a provider (n = 4 in 25-34, n = 6 in 35-44, n = 13 in 45-54, n = 39 in 55-64, n = 44 in 65-74, and n = 34 in ≥75-year olds), indicating a gap in access to treatment. The most common reason selected for not accessing care for ED concerns was a lack of need to see a provider in the past year.

Clinical Implications: The discrepancy between ED self-report and medical diagnosis is critical, given that ED can be an indication of underlying health risks.

Strengths And Limitations: This study is the first nationally representative update to information regarding the prevalence of ED in almost 2 decades. Standard administration of the IIEF-5 is limited to participants who have had sex in the last 6 months, so these rates do not include those men with ED who have been avoiding penetrative sex for a significant time.

Conclusion: The results indicate that ED prevalence and severity remain highest in older age groups and that most individuals who meet criteria for ED have not sought medical care related to this concern.

Citing Articles

Association of Sexual Health and Mental Health in Erectile Dysfunction: Expert Opinion From the Indian Context.

Vasan S, Pandey S, Rao S, Gupte D, Gangavaram R, Saxena A Cureus. 2025; 17(1):e77851.

PMID: 39991330 PMC: 11845324. DOI: 10.7759/cureus.77851.


Hormones, Age, and Erectile Dysfunction: Should Routine Testing Be Part of the Initial Evaluation?.

Porav-Hodade D, Gherasim R, Kosovski I, Voidazan T, Crisan N, Bogdan P Diagnostics (Basel). 2025; 15(3).

PMID: 39941224 PMC: 11816566. DOI: 10.3390/diagnostics15030294.


Molecular docking and network pharmacology research on the Danggui Sini Decoction's mechanism of action for treating erectile dysfunction.

Yan X, Zhang Y, Mo J, Xu L, Shi K, Zhou Y Medicine (Baltimore). 2025; 103(47):e40529.

PMID: 39809170 PMC: 11596949. DOI: 10.1097/MD.0000000000040529.


The relationship between complete blood cell count-derived inflammatory biomarkers and erectile dysfunction in the United States.

Zhang Y, Li T, Chen Q, Shen M, Fu X, Liu C Sci Rep. 2024; 14(1):32014.

PMID: 39738513 PMC: 11685723. DOI: 10.1038/s41598-024-83733-5.


Computational Investigation of the Therapeutic Potential of in the Management of Erectile Dysfunction.

Ejeje J, Agbebi E, Mathenjwa-Goqo M, Oje O, Agboinghale P, Ebe I Int J Mol Sci. 2024; 25(22).

PMID: 39596427 PMC: 11594949. DOI: 10.3390/ijms252212362.